Should I buy or sell QuidelOrtho stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for QuidelOrtho in the last year. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" QDEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QDEL, but not buy additional shares or sell existing shares. View QDEL analyst ratings or view top-rated stocks .

What is QuidelOrtho's stock price target for 2024?

7 brokers have issued 1-year price targets for QuidelOrtho's stock. Their QDEL share price targets range from $37.00 to $81.00. On average, they expect the company's stock price to reach $61.60 in the next twelve months. This suggests a possible upside of 59.1% from the stock's current price. View analysts price targets for QDEL or view top-rated stocks among Wall Street analysts .

How have QDEL shares performed in 2024?

QuidelOrtho's stock was trading at $73.70 on January 1st, 2024. Since then, QDEL shares have decreased by 47.5% and is now trading at $38.71. View the best growth stocks for 2024 here .

When is QuidelOrtho's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our QDEL earnings forecast .

How were QuidelOrtho's earnings last quarter?

QuidelOrtho Co. (NASDAQ:QDEL) announced its earnings results on Tuesday, February, 13th. The company reported $1.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.01 by $0.84. The firm earned $742.60 million during the quarter, compared to analysts' expectations of $796.91 million. QuidelOrtho had a positive trailing twelve-month return on equity of 5.54% and a negative net margin of 0.34%. The company's quarterly revenue was down 14.3% on a year-over-year basis. During the same period last year, the firm earned $1.74 EPS.

What ETFs hold QuidelOrtho's stock?

ETFs with the largest weight of QuidelOrtho (NASDAQ:QDEL) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM) , First Trust Health Care AlphaDEX Fund (FXH) , SPDR S&P Health Care Equipment ETF (XHE) , First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and Ballast Small/Mid Cap ETF (MGMT) . iShares U.S. Medical Devices ETF (IHI) .

What guidance has QuidelOrtho issued on next quarter's earnings?

QuidelOrtho updated its FY 2024 earnings guidance on Tuesday, February, 13th. The company provided EPS guidance of 2.400-3.070 for the period, compared to the consensus estimate of 5.070. The company issued revenue guidance of $2.8 billion-$3.1 billion, compared to the consensus revenue estimate of $3.0 billion.

What is Doug Bryant's approval rating as QuidelOrtho's CEO?

47 employees have rated QuidelOrtho Chief Executive Officer Doug Bryant on Glassdoor.com . Doug Bryant has an approval rating of 76% among the company's employees.

What other stocks do shareholders of QuidelOrtho own?

Based on aggregate information from My MarketBeat watchlists, some companies that other QuidelOrtho investors own include NVIDIA (NVDA) , DocuSign (DOCU) , Tesla (TSLA) , PayPal (PYPL) , Shopify (SHOP) , Block (SQ) , Teladoc Health (TDOC) , Netflix (NFLX) , Advanced Micro Devices (AMD) and Zoom Video Communications (ZM) .

Who are QuidelOrtho's major shareholders?

QuidelOrtho's stock is owned by many different institutional and retail investors. Top institutional investors include CWM LLC (0.00%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Charles P Slacik , Joseph M Busky, Mary Lake Ph D Polan and William J Ferenczy . View institutional ownership trends .

How do I buy shares of QuidelOrtho?

Shares of QDEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:QDEL

QuidelOrtho (QDEL) Stock Price, News & Analysis

→ Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad)

Free QDEL Stock Alerts

$38.71

-1.59 (-3.95%)

(As of 04/17/2024 ET)

Compare

Today's Range: $38.67
▼
$40.35
50-Day Range: $38.71
▼
$69.54
52-Week Range: $38.67
▼
$95.02

Volume: 754,587 shs
Average Volume: 835,511 shs
Market Capitalization: $2.59 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $61.60

Get QuidelOrtho alerts:

QuidelOrtho MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 59.1% Upside
$61.60 Price Target
Short Interest: Healthy
3.36% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.61
Upright™ Environmental Score
News Sentiment: 0.13
Based on 19 Articles This Week
Insider Trading: Acquiring Shares
$99,652 Bought Last Quarter
Proj. Earnings Growth: 73.73%
From $2.36 to $4.10 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.91 out of 5 stars

Medical Sector

17th out of 913 stocks

Diagnostic Substances Industry

1st out of 11 stocks

4.0

Analyst's Opinion

Consensus Rating
QuidelOrtho has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 3 hold ratings, and 2 sell ratings.
Amount of Analyst Coverage
QuidelOrtho has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
3.36% of the outstanding shares of QuidelOrtho have been sold short.
Short Interest Ratio / Days to Cover
QuidelOrtho has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in QuidelOrtho has recently decreased by 7.79%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
QuidelOrtho does not currently pay a dividend.
Dividend Growth
QuidelOrtho does not have a long track record of dividend growth.

3.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
QuidelOrtho has received a 49.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Sexually transmitted diseases quick tests", "Lactose intolerance quick tests", and "Respiratory tract infection tests" products. See details.
Environmental Sustainability
The Environmental Impact score for QuidelOrtho is -2.61.

1.7

News and Social Media Coverage

News Sentiment
QuidelOrtho has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 19 news articles for QuidelOrtho this week, compared to 4 articles on an average week.
Search Interest
Only 3 people have searched for QDEL on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added QuidelOrtho to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, QuidelOrtho insiders have bought more of their company's stock than they have sold. Specifically, they have bought $99,652.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 1.00% of the stock of QuidelOrtho is held by insiders.
Percentage Held by Institutions
99.00% of the stock of QuidelOrtho is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for QuidelOrtho are expected to grow by 73.73% in the coming year, from $2.36 to $4.10 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of QuidelOrtho is -241.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of QuidelOrtho is -241.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
QuidelOrtho has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About QuidelOrtho Stock (NASDAQ:QDEL)

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.

QDEL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

QDEL Stock News Headlines

April 17, 2024 | markets.businessinsider.com

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the Firm

April 17, 2024 | businesswire.com

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of QuidelOrtho Corporation (QDEL) Investors

April 18, 2024 | Tips4Traders (Ad)

Uncover this 2024 Hidden Gem

Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.

April 17, 2024 | businesswire.com

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of QuidelOrtho Corporation (QDEL) Investors

April 17, 2024 | finance.yahoo.com

QuidelOrtho To Report First Quarter 2024 Financial Results

April 17, 2024 | nasdaq.com

Benjamin Graham Detailed Fundamental Analysis - QDEL

April 17, 2024 | markets.businessinsider.com

IMPORTANT DEADLINE ALERT: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the Firm

April 16, 2024 | stockhouse.com

QDEL DEADLINE ALERT: Bernstein Liebhard LLP Reminds QuidelOrtho Corporation Investors of Upcoming Deadline

April 18, 2024 | Tips4Traders (Ad)

Uncover this 2024 Hidden Gem

April 16, 2024 | msn.com

Class Action Filed Against QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) Seeking Recovery for Investors – Contact Levi & Korsinsky LLP

April 16, 2024 | businesswire.com

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of QuidelOrtho Corporation (QDEL) Investors

April 16, 2024 | markets.businessinsider.com

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the Firm

April 15, 2024 | prnewswire.com

QDEL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that QuidelOrtho Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

April 15, 2024 | businesswire.com

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – QDEL

April 13, 2024 | businesswire.com

Labaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against QuidelOrtho Corporation and Certain Executives

April 13, 2024 | seekingalpha.com

QuidelOrtho: Attractive Valuation Despite Weak Performance

April 13, 2024 | ca.finance.yahoo.com

CAH May 2024 120.000 call

April 12, 2024 | businesswire.com

Labaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against QuidelOrtho Company and Certain Executives

April 12, 2024 | investing.com

QuidelOrtho launches rapid fentanyl test for hospitals

April 10, 2024 | prnewswire.com

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation - QDEL

April 10, 2024 | finance.yahoo.com

QuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership Assay

April 3, 2024 | markets.businessinsider.com

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation - QDEL

April 3, 2024 | finance.yahoo.com

This QuidelOrtho Insider Increased Their Holding By 54% Last Year

April 2, 2024 | prnewswire.com

ROSEN, LEADING INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation - QDEL

April 2, 2024 | msn.com

QuidelOrtho stock falls 11% on Savanna PVP4+ assay update

April 2, 2024 | msn.com

What's Going With COVID-19 Test Maker QuidelOrtho Stock On Tuesday?

April 2, 2024 | markets.businessinsider.com

QuidelOrtho Receives FDA Clearance For QuickVue COVID-19 Test - Quick Facts

See More Headlines

Receive QDEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for QuidelOrtho and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/13/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Diagnostic substances
Sub-Industry: Health Care Supplies
Current Symbol: NASDAQ:QDEL
CUSIP: 74838J10
CIK: 353569
Web: www.quidel.com
Phone: (800) 874-1517
Fax: 858-453-4338
Employees: 7,100
Year Founded: 1979

Price Target and Rating

Average Stock Price Target: $61.60
High Stock Price Target: $81.00
Low Stock Price Target: $37.00
Potential Upside/Downside: +59.1%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.16)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 16.40
P/E Growth: N/A
Net Income: $-10,100,000.00
Net Margins: -0.34%
Pretax Margin: -0.97%
Return on Equity: 5.54%
Return on Assets: 3.21%

Debt

Debt-to-Equity Ratio: 0.45
Current Ratio: 1.57
Quick Ratio: 0.88

Sales & Book Value

Annual Sales: $3.00 billion
Price / Sales: 0.86
Cash Flow: $10.27 per share
Price / Cash Flow: 3.77
Book Value: $74.92 per share
Price / Book: 0.52

Miscellaneous

Outstanding Shares: 66,880,000
Free Float: 66,210,000
Market Cap: $2.59 billion
Optionable: Optionable
Beta: 0.11

Social Links

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Robert J. Bujarski J.D. (Age 55)
Interim President, Executive VP & COO
Comp: $2.62M
Mr. Joseph M. Busky CPA (Age 56)
Chief Financial Officer
Comp: $1.47M
Ms. Michelle A. Hodges (Age 63)
Senior VP, General Counsel & Secretary
Comp: $1.8M
Dr. Werner Kroll Ph.D. (Age 67)
Senior Vice President of Research & Development
Comp: $1.25M
Mr. Michael S. Iskra (Age 54)
Interim CEO, Executive VP & Chief Commercial Officer
Ms. Louise M. Brandy
Chief Information Officer
Mr. Patrick E. Klein
Chief Administrative Officer
Ruben Argueta
Director of Investor Relations
Mr. William J. Ferenczy (Age 68)
Point of Care Business Unit Leader
Ms. Tamara A. Ranalli (Age 51)
Molecular Diagnostics Business Unit Leader

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

QDEL Stock Analysis - Frequently Asked Questions

Should I buy or sell QuidelOrtho stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for QuidelOrtho in the last year. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" QDEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QDEL, but not buy additional shares or sell existing shares.
View QDEL analyst ratings or view top-rated stocks.
What is QuidelOrtho's stock price target for 2024?: 7 brokers have issued 1-year price targets for QuidelOrtho's stock. Their QDEL share price targets range from $37.00 to $81.00. On average, they expect the company's stock price to reach $61.60 in the next twelve months. This suggests a possible upside of 59.1% from the stock's current price.
View analysts price targets for QDEL or view top-rated stocks among Wall Street analysts.
How have QDEL shares performed in 2024?: QuidelOrtho's stock was trading at $73.70 on January 1st, 2024. Since then, QDEL shares have decreased by 47.5% and is now trading at $38.71.
View the best growth stocks for 2024 here.
When is QuidelOrtho's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our QDEL earnings forecast.
How were QuidelOrtho's earnings last quarter?: QuidelOrtho Co. (NASDAQ:QDEL) announced its earnings results on Tuesday, February, 13th. The company reported $1.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.01 by $0.84. The firm earned $742.60 million during the quarter, compared to analysts' expectations of $796.91 million. QuidelOrtho had a positive trailing twelve-month return on equity of 5.54% and a negative net margin of 0.34%. The company's quarterly revenue was down 14.3% on a year-over-year basis. During the same period last year, the firm earned $1.74 EPS.
What ETFs hold QuidelOrtho's stock?: ETFs with the largest weight of QuidelOrtho (NASDAQ:QDEL) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), First Trust Health Care AlphaDEX Fund (FXH), SPDR S&P Health Care Equipment ETF (XHE), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and Ballast Small/Mid Cap ETF (MGMT).iShares U.S. Medical Devices ETF (IHI).

What guidance has QuidelOrtho issued on next quarter's earnings?: QuidelOrtho updated its FY 2024 earnings guidance on Tuesday, February, 13th. The company provided EPS guidance of 2.400-3.070 for the period, compared to the consensus estimate of 5.070. The company issued revenue guidance of $2.8 billion-$3.1 billion, compared to the consensus revenue estimate of $3.0 billion.
What is Doug Bryant's approval rating as QuidelOrtho's CEO?: 47 employees have rated QuidelOrtho Chief Executive Officer Doug Bryant on Glassdoor.com. Doug Bryant has an approval rating of 76% among the company's employees.
What other stocks do shareholders of QuidelOrtho own?: Based on aggregate information from My MarketBeat watchlists, some companies that other QuidelOrtho investors own include NVIDIA (NVDA), DocuSign (DOCU), Tesla (TSLA), PayPal (PYPL), Shopify (SHOP), Block (SQ), Teladoc Health (TDOC), Netflix (NFLX), Advanced Micro Devices (AMD) and Zoom Video Communications (ZM).
Who are QuidelOrtho's major shareholders?: QuidelOrtho's stock is owned by many different institutional and retail investors. Top institutional investors include CWM LLC (0.00%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Charles P Slacik, Joseph M Busky, Mary Lake Ph D Polan and William J Ferenczy.
View institutional ownership trends.
How do I buy shares of QuidelOrtho?: Shares of QDEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:QDEL) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial